nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—ALB—melanoma	0.347	1	CbGaD
Valsartan—SLCO1B3—Docetaxel—melanoma	0.175	0.518	CbGbCtD
Valsartan—ALB—Vemurafenib—melanoma	0.163	0.482	CbGbCtD
Valsartan—Swelling—Carmustine—melanoma	0.00103	0.00474	CcSEcCtD
Valsartan—Dysgeusia—Vemurafenib—melanoma	0.00101	0.00466	CcSEcCtD
Valsartan—Back pain—Vemurafenib—melanoma	0.000997	0.00461	CcSEcCtD
Valsartan—Ageusia—Docetaxel—melanoma	0.000989	0.00457	CcSEcCtD
Valsartan—Hyponatraemia—Carmustine—melanoma	0.000909	0.0042	CcSEcCtD
Valsartan—Cough—Vemurafenib—melanoma	0.000899	0.00416	CcSEcCtD
Valsartan—Myalgia—Vemurafenib—melanoma	0.000877	0.00405	CcSEcCtD
Valsartan—Arthralgia—Vemurafenib—melanoma	0.000877	0.00405	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.000871	0.00403	CcSEcCtD
Valsartan—Drug interaction—Docetaxel—melanoma	0.000864	0.00399	CcSEcCtD
Valsartan—Anaphylactic shock—Vemurafenib—melanoma	0.000841	0.00389	CcSEcCtD
Valsartan—Infection—Vemurafenib—melanoma	0.000835	0.00386	CcSEcCtD
Valsartan—Nervous system disorder—Vemurafenib—melanoma	0.000825	0.00381	CcSEcCtD
Valsartan—Skin disorder—Vemurafenib—melanoma	0.000817	0.00378	CcSEcCtD
Valsartan—Blood pressure increased—Docetaxel—melanoma	0.000801	0.0037	CcSEcCtD
Valsartan—Muscular weakness—Carmustine—melanoma	0.000798	0.00369	CcSEcCtD
Valsartan—Hypotension—Vemurafenib—melanoma	0.000786	0.00363	CcSEcCtD
Valsartan—Neutropenia—Dactinomycin—melanoma	0.000781	0.00361	CcSEcCtD
Valsartan—Muscular weakness—Temozolomide—melanoma	0.000771	0.00356	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Vemurafenib—melanoma	0.000766	0.00354	CcSEcCtD
Valsartan—Neutropenia—Carmustine—melanoma	0.000731	0.00338	CcSEcCtD
Valsartan—Decreased appetite—Vemurafenib—melanoma	0.000731	0.00338	CcSEcCtD
Valsartan—Bronchitis—Temozolomide—melanoma	0.000727	0.00336	CcSEcCtD
Valsartan—Gastrointestinal disorder—Vemurafenib—melanoma	0.000726	0.00336	CcSEcCtD
Valsartan—Fatigue—Vemurafenib—melanoma	0.000725	0.00335	CcSEcCtD
Valsartan—Haemoglobin—Bleomycin—melanoma	0.000721	0.00333	CcSEcCtD
Valsartan—Constipation—Vemurafenib—melanoma	0.000719	0.00332	CcSEcCtD
Valsartan—Haemorrhage—Bleomycin—melanoma	0.000717	0.00331	CcSEcCtD
Valsartan—Neutropenia—Temozolomide—melanoma	0.000707	0.00327	CcSEcCtD
Valsartan—Upper respiratory tract infection—Temozolomide—melanoma	0.000702	0.00325	CcSEcCtD
Valsartan—Erectile dysfunction—Temozolomide—melanoma	0.000696	0.00322	CcSEcCtD
Valsartan—Photosensitivity reaction—Temozolomide—melanoma	0.00069	0.00319	CcSEcCtD
Valsartan—Renal failure—Carmustine—melanoma	0.000685	0.00317	CcSEcCtD
Valsartan—Infestation NOS—Temozolomide—melanoma	0.000674	0.00311	CcSEcCtD
Valsartan—Infestation—Temozolomide—melanoma	0.000674	0.00311	CcSEcCtD
Valsartan—Hepatitis—Dactinomycin—melanoma	0.000669	0.00309	CcSEcCtD
Valsartan—Pharyngitis—Dactinomycin—melanoma	0.000664	0.00307	CcSEcCtD
Valsartan—Swelling—Docetaxel—melanoma	0.000659	0.00305	CcSEcCtD
Valsartan—Alopecia—Bleomycin—melanoma	0.000634	0.00293	CcSEcCtD
Valsartan—Sinusitis—Temozolomide—melanoma	0.000632	0.00292	CcSEcCtD
Valsartan—Haemoglobin—Carmustine—melanoma	0.000629	0.00291	CcSEcCtD
Valsartan—Haemorrhage—Carmustine—melanoma	0.000626	0.00289	CcSEcCtD
Valsartan—Hypersensitivity—Vemurafenib—melanoma	0.00062	0.00286	CcSEcCtD
Valsartan—Connective tissue disorder—Carmustine—melanoma	0.000615	0.00284	CcSEcCtD
Valsartan—Atrial fibrillation—Docetaxel—melanoma	0.000614	0.00284	CcSEcCtD
Valsartan—Renal impairment—Docetaxel—melanoma	0.000611	0.00282	CcSEcCtD
Valsartan—Dermatitis bullous—Docetaxel—melanoma	0.000608	0.00281	CcSEcCtD
Valsartan—Haemoglobin—Temozolomide—melanoma	0.000608	0.00281	CcSEcCtD
Valsartan—Haemorrhage—Temozolomide—melanoma	0.000605	0.0028	CcSEcCtD
Valsartan—Hepatitis—Temozolomide—melanoma	0.000605	0.0028	CcSEcCtD
Valsartan—Asthenia—Vemurafenib—melanoma	0.000603	0.00279	CcSEcCtD
Valsartan—Pharyngitis—Temozolomide—melanoma	0.0006	0.00277	CcSEcCtD
Valsartan—Urinary tract disorder—Temozolomide—melanoma	0.000597	0.00276	CcSEcCtD
Valsartan—Cardiac failure—Docetaxel—melanoma	0.000596	0.00275	CcSEcCtD
Valsartan—Pruritus—Vemurafenib—melanoma	0.000595	0.00275	CcSEcCtD
Valsartan—Connective tissue disorder—Temozolomide—melanoma	0.000594	0.00275	CcSEcCtD
Valsartan—Urethral disorder—Temozolomide—melanoma	0.000593	0.00274	CcSEcCtD
Valsartan—Alopecia—Dactinomycin—melanoma	0.000591	0.00273	CcSEcCtD
Valsartan—Hyponatraemia—Docetaxel—melanoma	0.000584	0.0027	CcSEcCtD
Valsartan—Diarrhoea—Vemurafenib—melanoma	0.000575	0.00266	CcSEcCtD
Valsartan—Cardiac disorder—Temozolomide—melanoma	0.000561	0.00259	CcSEcCtD
Valsartan—Dizziness—Vemurafenib—melanoma	0.000556	0.00257	CcSEcCtD
Valsartan—Alopecia—Carmustine—melanoma	0.000553	0.00256	CcSEcCtD
Valsartan—Angiopathy—Temozolomide—melanoma	0.000549	0.00254	CcSEcCtD
Valsartan—Mental disorder—Carmustine—melanoma	0.000548	0.00253	CcSEcCtD
Valsartan—Immune system disorder—Temozolomide—melanoma	0.000546	0.00253	CcSEcCtD
Valsartan—Mediastinal disorder—Temozolomide—melanoma	0.000545	0.00252	CcSEcCtD
Valsartan—Malnutrition—Carmustine—melanoma	0.000545	0.00252	CcSEcCtD
Valsartan—Cough—Bleomycin—melanoma	0.000545	0.00252	CcSEcCtD
Valsartan—Vomiting—Vemurafenib—melanoma	0.000535	0.00247	CcSEcCtD
Valsartan—Alopecia—Temozolomide—melanoma	0.000535	0.00247	CcSEcCtD
Valsartan—Myalgia—Bleomycin—melanoma	0.000531	0.00246	CcSEcCtD
Valsartan—Chest pain—Bleomycin—melanoma	0.000531	0.00246	CcSEcCtD
Valsartan—Abdominal pain upper—Docetaxel—melanoma	0.000531	0.00245	CcSEcCtD
Valsartan—Orthostatic hypotension—Docetaxel—melanoma	0.000531	0.00245	CcSEcCtD
Valsartan—Rash—Vemurafenib—melanoma	0.00053	0.00245	CcSEcCtD
Valsartan—Mental disorder—Temozolomide—melanoma	0.00053	0.00245	CcSEcCtD
Valsartan—Dermatitis—Vemurafenib—melanoma	0.00053	0.00245	CcSEcCtD
Valsartan—Back pain—Carmustine—melanoma	0.000527	0.00244	CcSEcCtD
Valsartan—Headache—Vemurafenib—melanoma	0.000527	0.00243	CcSEcCtD
Valsartan—Malnutrition—Temozolomide—melanoma	0.000527	0.00243	CcSEcCtD
Valsartan—Cramp muscle—Docetaxel—melanoma	0.000524	0.00242	CcSEcCtD
Valsartan—Dysgeusia—Temozolomide—melanoma	0.000516	0.00238	CcSEcCtD
Valsartan—Vision blurred—Carmustine—melanoma	0.000514	0.00237	CcSEcCtD
Valsartan—Anaphylactic shock—Bleomycin—melanoma	0.00051	0.00235	CcSEcCtD
Valsartan—Oedema—Bleomycin—melanoma	0.00051	0.00235	CcSEcCtD
Valsartan—Back pain—Temozolomide—melanoma	0.000509	0.00235	CcSEcCtD
Valsartan—Infection—Bleomycin—melanoma	0.000506	0.00234	CcSEcCtD
Valsartan—Nausea—Vemurafenib—melanoma	0.0005	0.00231	CcSEcCtD
Valsartan—Thrombocytopenia—Bleomycin—melanoma	0.000499	0.00231	CcSEcCtD
Valsartan—Vision blurred—Temozolomide—melanoma	0.000496	0.00229	CcSEcCtD
Valsartan—Myalgia—Dactinomycin—melanoma	0.000496	0.00229	CcSEcCtD
Valsartan—Anorexia—Bleomycin—melanoma	0.000486	0.00224	CcSEcCtD
Valsartan—Angioedema—Temozolomide—melanoma	0.000481	0.00222	CcSEcCtD
Valsartan—Hypotension—Bleomycin—melanoma	0.000476	0.0022	CcSEcCtD
Valsartan—Oedema—Dactinomycin—melanoma	0.000475	0.0022	CcSEcCtD
Valsartan—Vertigo—Temozolomide—melanoma	0.000473	0.00219	CcSEcCtD
Valsartan—Infection—Dactinomycin—melanoma	0.000472	0.00218	CcSEcCtD
Valsartan—Neutropenia—Docetaxel—melanoma	0.00047	0.00217	CcSEcCtD
Valsartan—Palpitations—Temozolomide—melanoma	0.000465	0.00215	CcSEcCtD
Valsartan—Thrombocytopenia—Dactinomycin—melanoma	0.000465	0.00215	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Bleomycin—melanoma	0.000464	0.00215	CcSEcCtD
Valsartan—Myalgia—Carmustine—melanoma	0.000464	0.00214	CcSEcCtD
Valsartan—Chest pain—Carmustine—melanoma	0.000464	0.00214	CcSEcCtD
Valsartan—Anxiety—Carmustine—melanoma	0.000462	0.00214	CcSEcCtD
Valsartan—Cough—Temozolomide—melanoma	0.00046	0.00212	CcSEcCtD
Valsartan—Paraesthesia—Bleomycin—melanoma	0.000458	0.00211	CcSEcCtD
Valsartan—Dyspnoea—Bleomycin—melanoma	0.000454	0.0021	CcSEcCtD
Valsartan—Anorexia—Dactinomycin—melanoma	0.000453	0.00209	CcSEcCtD
Valsartan—Arthralgia—Temozolomide—melanoma	0.000448	0.00207	CcSEcCtD
Valsartan—Myalgia—Temozolomide—melanoma	0.000448	0.00207	CcSEcCtD
Valsartan—Infestation NOS—Docetaxel—melanoma	0.000448	0.00207	CcSEcCtD
Valsartan—Infestation—Docetaxel—melanoma	0.000448	0.00207	CcSEcCtD
Valsartan—Anxiety—Temozolomide—melanoma	0.000447	0.00206	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000445	0.00206	CcSEcCtD
Valsartan—Oedema—Carmustine—melanoma	0.000445	0.00206	CcSEcCtD
Valsartan—Decreased appetite—Bleomycin—melanoma	0.000443	0.00205	CcSEcCtD
Valsartan—Infection—Carmustine—melanoma	0.000442	0.00204	CcSEcCtD
Valsartan—Renal failure—Docetaxel—melanoma	0.000441	0.00204	CcSEcCtD
Valsartan—Dry mouth—Temozolomide—melanoma	0.000438	0.00203	CcSEcCtD
Valsartan—Thrombocytopenia—Carmustine—melanoma	0.000435	0.00201	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000433	0.002	CcSEcCtD
Valsartan—Oedema—Temozolomide—melanoma	0.00043	0.00199	CcSEcCtD
Valsartan—Anaphylactic shock—Temozolomide—melanoma	0.00043	0.00199	CcSEcCtD
Valsartan—Infection—Temozolomide—melanoma	0.000427	0.00197	CcSEcCtD
Valsartan—Anorexia—Carmustine—melanoma	0.000424	0.00196	CcSEcCtD
Valsartan—Epistaxis—Docetaxel—melanoma	0.000423	0.00195	CcSEcCtD
Valsartan—Nervous system disorder—Temozolomide—melanoma	0.000421	0.00195	CcSEcCtD
Valsartan—Thrombocytopenia—Temozolomide—melanoma	0.000421	0.00194	CcSEcCtD
Valsartan—Skin disorder—Temozolomide—melanoma	0.000417	0.00193	CcSEcCtD
Valsartan—Hypotension—Carmustine—melanoma	0.000416	0.00192	CcSEcCtD
Valsartan—Decreased appetite—Dactinomycin—melanoma	0.000413	0.00191	CcSEcCtD
Valsartan—Fatigue—Dactinomycin—melanoma	0.00041	0.00189	CcSEcCtD
Valsartan—Anorexia—Temozolomide—melanoma	0.00041	0.00189	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Carmustine—melanoma	0.000405	0.00187	CcSEcCtD
Valsartan—Urticaria—Bleomycin—melanoma	0.000405	0.00187	CcSEcCtD
Valsartan—Haemoglobin—Docetaxel—melanoma	0.000404	0.00187	CcSEcCtD
Valsartan—Rhinitis—Docetaxel—melanoma	0.000403	0.00186	CcSEcCtD
Valsartan—Haemorrhage—Docetaxel—melanoma	0.000402	0.00186	CcSEcCtD
Valsartan—Hepatitis—Docetaxel—melanoma	0.000402	0.00186	CcSEcCtD
Valsartan—Insomnia—Carmustine—melanoma	0.000402	0.00186	CcSEcCtD
Valsartan—Paraesthesia—Carmustine—melanoma	0.000399	0.00185	CcSEcCtD
Valsartan—Pharyngitis—Docetaxel—melanoma	0.000399	0.00185	CcSEcCtD
Valsartan—Urinary tract disorder—Docetaxel—melanoma	0.000397	0.00184	CcSEcCtD
Valsartan—Dyspnoea—Carmustine—melanoma	0.000397	0.00183	CcSEcCtD
Valsartan—Somnolence—Carmustine—melanoma	0.000395	0.00183	CcSEcCtD
Valsartan—Connective tissue disorder—Docetaxel—melanoma	0.000395	0.00183	CcSEcCtD
Valsartan—Urethral disorder—Docetaxel—melanoma	0.000394	0.00182	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Temozolomide—melanoma	0.000392	0.00181	CcSEcCtD
Valsartan—Insomnia—Temozolomide—melanoma	0.000389	0.0018	CcSEcCtD
Valsartan—Gastrointestinal pain—Dactinomycin—melanoma	0.000389	0.0018	CcSEcCtD
Valsartan—Decreased appetite—Carmustine—melanoma	0.000387	0.00179	CcSEcCtD
Valsartan—Paraesthesia—Temozolomide—melanoma	0.000386	0.00178	CcSEcCtD
Valsartan—Gastrointestinal disorder—Carmustine—melanoma	0.000384	0.00177	CcSEcCtD
Valsartan—Dyspnoea—Temozolomide—melanoma	0.000383	0.00177	CcSEcCtD
Valsartan—Somnolence—Temozolomide—melanoma	0.000382	0.00177	CcSEcCtD
Valsartan—Constipation—Carmustine—melanoma	0.00038	0.00176	CcSEcCtD
Valsartan—Dyspepsia—Temozolomide—melanoma	0.000378	0.00175	CcSEcCtD
Valsartan—Abdominal pain—Dactinomycin—melanoma	0.000376	0.00174	CcSEcCtD
Valsartan—Hypersensitivity—Bleomycin—melanoma	0.000375	0.00173	CcSEcCtD
Valsartan—Decreased appetite—Temozolomide—melanoma	0.000374	0.00173	CcSEcCtD
Valsartan—Cardiac disorder—Docetaxel—melanoma	0.000373	0.00173	CcSEcCtD
Valsartan—Gastrointestinal disorder—Temozolomide—melanoma	0.000371	0.00171	CcSEcCtD
Valsartan—Fatigue—Temozolomide—melanoma	0.000371	0.00171	CcSEcCtD
Valsartan—Constipation—Temozolomide—melanoma	0.000368	0.0017	CcSEcCtD
Valsartan—Asthenia—Bleomycin—melanoma	0.000366	0.00169	CcSEcCtD
Valsartan—Angiopathy—Docetaxel—melanoma	0.000365	0.00169	CcSEcCtD
Valsartan—Gastrointestinal pain—Carmustine—melanoma	0.000364	0.00168	CcSEcCtD
Valsartan—Immune system disorder—Docetaxel—melanoma	0.000363	0.00168	CcSEcCtD
Valsartan—Mediastinal disorder—Docetaxel—melanoma	0.000363	0.00168	CcSEcCtD
Valsartan—Pruritus—Bleomycin—melanoma	0.00036	0.00167	CcSEcCtD
Valsartan—Alopecia—Docetaxel—melanoma	0.000355	0.00164	CcSEcCtD
Valsartan—Mental disorder—Docetaxel—melanoma	0.000352	0.00163	CcSEcCtD
Valsartan—Abdominal pain—Carmustine—melanoma	0.000352	0.00162	CcSEcCtD
Valsartan—Gastrointestinal pain—Temozolomide—melanoma	0.000351	0.00162	CcSEcCtD
Valsartan—Malnutrition—Docetaxel—melanoma	0.00035	0.00162	CcSEcCtD
Valsartan—Hypersensitivity—Dactinomycin—melanoma	0.00035	0.00162	CcSEcCtD
Valsartan—Dysgeusia—Docetaxel—melanoma	0.000343	0.00159	CcSEcCtD
Valsartan—Urticaria—Temozolomide—melanoma	0.000341	0.00158	CcSEcCtD
Valsartan—Asthenia—Dactinomycin—melanoma	0.000341	0.00158	CcSEcCtD
Valsartan—Abdominal pain—Temozolomide—melanoma	0.00034	0.00157	CcSEcCtD
Valsartan—Back pain—Docetaxel—melanoma	0.000339	0.00157	CcSEcCtD
Valsartan—Muscle spasms—Docetaxel—melanoma	0.000337	0.00156	CcSEcCtD
Valsartan—Hypersensitivity—Carmustine—melanoma	0.000328	0.00151	CcSEcCtD
Valsartan—Diarrhoea—Dactinomycin—melanoma	0.000325	0.0015	CcSEcCtD
Valsartan—Vomiting—Bleomycin—melanoma	0.000324	0.0015	CcSEcCtD
Valsartan—Rash—Bleomycin—melanoma	0.000321	0.00148	CcSEcCtD
Valsartan—Dermatitis—Bleomycin—melanoma	0.000321	0.00148	CcSEcCtD
Valsartan—Asthenia—Carmustine—melanoma	0.000319	0.00147	CcSEcCtD
Valsartan—Hypersensitivity—Temozolomide—melanoma	0.000317	0.00146	CcSEcCtD
Valsartan—Syncope—Docetaxel—melanoma	0.000314	0.00145	CcSEcCtD
Valsartan—Palpitations—Docetaxel—melanoma	0.000309	0.00143	CcSEcCtD
Valsartan—Asthenia—Temozolomide—melanoma	0.000308	0.00143	CcSEcCtD
Valsartan—Loss of consciousness—Docetaxel—melanoma	0.000308	0.00142	CcSEcCtD
Valsartan—Cough—Docetaxel—melanoma	0.000306	0.00141	CcSEcCtD
Valsartan—Diarrhoea—Carmustine—melanoma	0.000304	0.00141	CcSEcCtD
Valsartan—Pruritus—Temozolomide—melanoma	0.000304	0.00141	CcSEcCtD
Valsartan—Nausea—Bleomycin—melanoma	0.000303	0.0014	CcSEcCtD
Valsartan—Vomiting—Dactinomycin—melanoma	0.000302	0.0014	CcSEcCtD
Valsartan—Rash—Dactinomycin—melanoma	0.0003	0.00138	CcSEcCtD
Valsartan—Arthralgia—Docetaxel—melanoma	0.000298	0.00138	CcSEcCtD
Valsartan—Chest pain—Docetaxel—melanoma	0.000298	0.00138	CcSEcCtD
Valsartan—Myalgia—Docetaxel—melanoma	0.000298	0.00138	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000296	0.00137	CcSEcCtD
Valsartan—Dizziness—Carmustine—melanoma	0.000294	0.00136	CcSEcCtD
Valsartan—Diarrhoea—Temozolomide—melanoma	0.000294	0.00136	CcSEcCtD
Valsartan—Dry mouth—Docetaxel—melanoma	0.000292	0.00135	CcSEcCtD
Valsartan—Anaphylactic shock—Docetaxel—melanoma	0.000286	0.00132	CcSEcCtD
Valsartan—Oedema—Docetaxel—melanoma	0.000286	0.00132	CcSEcCtD
Valsartan—Dizziness—Temozolomide—melanoma	0.000284	0.00131	CcSEcCtD
Valsartan—Infection—Docetaxel—melanoma	0.000284	0.00131	CcSEcCtD
Valsartan—Vomiting—Carmustine—melanoma	0.000283	0.00131	CcSEcCtD
Valsartan—Nausea—Dactinomycin—melanoma	0.000282	0.0013	CcSEcCtD
Valsartan—Shock—Docetaxel—melanoma	0.000281	0.0013	CcSEcCtD
Valsartan—Rash—Carmustine—melanoma	0.00028	0.0013	CcSEcCtD
Valsartan—Nervous system disorder—Docetaxel—melanoma	0.00028	0.0013	CcSEcCtD
Valsartan—Dermatitis—Carmustine—melanoma	0.00028	0.00129	CcSEcCtD
Valsartan—Thrombocytopenia—Docetaxel—melanoma	0.00028	0.00129	CcSEcCtD
Valsartan—Headache—Carmustine—melanoma	0.000279	0.00129	CcSEcCtD
Valsartan—Skin disorder—Docetaxel—melanoma	0.000278	0.00128	CcSEcCtD
Valsartan—Vomiting—Temozolomide—melanoma	0.000273	0.00126	CcSEcCtD
Valsartan—Anorexia—Docetaxel—melanoma	0.000272	0.00126	CcSEcCtD
Valsartan—Rash—Temozolomide—melanoma	0.000271	0.00125	CcSEcCtD
Valsartan—Dermatitis—Temozolomide—melanoma	0.000271	0.00125	CcSEcCtD
Valsartan—Headache—Temozolomide—melanoma	0.000269	0.00124	CcSEcCtD
Valsartan—Hypotension—Docetaxel—melanoma	0.000267	0.00123	CcSEcCtD
Valsartan—Nausea—Carmustine—melanoma	0.000264	0.00122	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Docetaxel—melanoma	0.00026	0.0012	CcSEcCtD
Valsartan—Insomnia—Docetaxel—melanoma	0.000259	0.00119	CcSEcCtD
Valsartan—Paraesthesia—Docetaxel—melanoma	0.000257	0.00119	CcSEcCtD
Valsartan—Nausea—Temozolomide—melanoma	0.000255	0.00118	CcSEcCtD
Valsartan—Dyspnoea—Docetaxel—melanoma	0.000255	0.00118	CcSEcCtD
Valsartan—Somnolence—Docetaxel—melanoma	0.000254	0.00117	CcSEcCtD
Valsartan—Dyspepsia—Docetaxel—melanoma	0.000252	0.00116	CcSEcCtD
Valsartan—Decreased appetite—Docetaxel—melanoma	0.000248	0.00115	CcSEcCtD
Valsartan—Gastrointestinal disorder—Docetaxel—melanoma	0.000247	0.00114	CcSEcCtD
Valsartan—Fatigue—Docetaxel—melanoma	0.000246	0.00114	CcSEcCtD
Valsartan—Constipation—Docetaxel—melanoma	0.000244	0.00113	CcSEcCtD
Valsartan—Gastrointestinal pain—Docetaxel—melanoma	0.000234	0.00108	CcSEcCtD
Valsartan—Abdominal pain—Docetaxel—melanoma	0.000226	0.00104	CcSEcCtD
Valsartan—Hypersensitivity—Docetaxel—melanoma	0.000211	0.000973	CcSEcCtD
Valsartan—Asthenia—Docetaxel—melanoma	0.000205	0.000948	CcSEcCtD
Valsartan—Pruritus—Docetaxel—melanoma	0.000202	0.000935	CcSEcCtD
Valsartan—Diarrhoea—Docetaxel—melanoma	0.000196	0.000904	CcSEcCtD
Valsartan—Dizziness—Docetaxel—melanoma	0.000189	0.000874	CcSEcCtD
Valsartan—Vomiting—Docetaxel—melanoma	0.000182	0.00084	CcSEcCtD
Valsartan—Rash—Docetaxel—melanoma	0.00018	0.000833	CcSEcCtD
Valsartan—Dermatitis—Docetaxel—melanoma	0.00018	0.000832	CcSEcCtD
Valsartan—Headache—Docetaxel—melanoma	0.000179	0.000828	CcSEcCtD
Valsartan—Nausea—Docetaxel—melanoma	0.00017	0.000785	CcSEcCtD
Valsartan—ALB—Metabolism—PLCB4—melanoma	3.81e-05	0.000387	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CG—melanoma	3.81e-05	0.000387	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CD—melanoma	3.79e-05	0.000385	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IFNA1—melanoma	3.78e-05	0.000384	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—FASN—melanoma	3.74e-05	0.00038	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—VCAN—melanoma	3.74e-05	0.00038	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IL6—melanoma	3.72e-05	0.000379	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SYK—melanoma	3.72e-05	0.000378	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CD—melanoma	3.69e-05	0.000375	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SYK—melanoma	3.67e-05	0.000373	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ITGAV—melanoma	3.65e-05	0.000371	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT3—melanoma	3.65e-05	0.000371	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NGFR—melanoma	3.65e-05	0.000371	CbGpPWpGaD
Valsartan—ALB—Hemostasis—ITGAV—melanoma	3.6e-05	0.000366	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT3—melanoma	3.6e-05	0.000366	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC6A11—melanoma	3.58e-05	0.000364	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIP4K2A—melanoma	3.58e-05	0.000364	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	3.54e-05	0.00036	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IFNA2—melanoma	3.52e-05	0.000358	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC5A5—melanoma	3.5e-05	0.000356	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.49e-05	0.000355	CbGpPWpGaD
Valsartan—ALB—Metabolism—MTAP—melanoma	3.49e-05	0.000354	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—melanoma	3.42e-05	0.000347	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	3.41e-05	0.000346	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SOCS1—melanoma	3.38e-05	0.000343	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—MAP2K1—melanoma	3.37e-05	0.000342	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—S100B—melanoma	3.37e-05	0.000342	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CD—melanoma	3.35e-05	0.00034	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	3.31e-05	0.000337	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CB—melanoma	3.3e-05	0.000336	CbGpPWpGaD
Valsartan—ALB—Hemostasis—ITGB1—melanoma	3.27e-05	0.000333	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ABCB1—melanoma	3.26e-05	0.000331	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ERBB4—melanoma	3.22e-05	0.000327	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CB—melanoma	3.21e-05	0.000326	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDKN2B—melanoma	3.19e-05	0.000325	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP17A1—melanoma	3.16e-05	0.000321	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PLCB4—melanoma	3.12e-05	0.000317	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	3.11e-05	0.000316	CbGpPWpGaD
Valsartan—ALB—Metabolism—PHGDH—melanoma	3.11e-05	0.000316	CbGpPWpGaD
Valsartan—ALB—Metabolism—LUM—melanoma	3.11e-05	0.000316	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CD86—melanoma	3.09e-05	0.000314	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCL8—melanoma	3.09e-05	0.000314	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—melanoma	3.07e-05	0.000312	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EDN1—melanoma	3.06e-05	0.000311	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—FASN—melanoma	3.06e-05	0.000311	CbGpPWpGaD
Valsartan—ALB—Metabolism—HPSE—melanoma	3.05e-05	0.00031	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—IL2—melanoma	3.03e-05	0.000308	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PRKCA—melanoma	3e-05	0.000305	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FGF1—melanoma	2.99e-05	0.000304	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CSF2—melanoma	2.99e-05	0.000304	CbGpPWpGaD
Valsartan—ALB—Hemostasis—HGF—melanoma	2.99e-05	0.000304	CbGpPWpGaD
Valsartan—ALB—Metabolism—CUBN—melanoma	2.99e-05	0.000304	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GNA11—melanoma	2.98e-05	0.000303	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ERCC2—melanoma	2.97e-05	0.000302	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CSF2—melanoma	2.96e-05	0.000301	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—IL2—melanoma	2.95e-05	0.0003	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIP4K2A—melanoma	2.93e-05	0.000298	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC6A11—melanoma	2.93e-05	0.000298	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—E2F1—melanoma	2.93e-05	0.000298	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—ALB—melanoma	2.92e-05	0.000297	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CB—melanoma	2.92e-05	0.000296	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—FASN—melanoma	2.92e-05	0.000296	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PDGFRA—melanoma	2.9e-05	0.000295	CbGpPWpGaD
Valsartan—ALB—Metabolism—SDHD—melanoma	2.89e-05	0.000294	CbGpPWpGaD
Valsartan—ALB—Metabolism—BSG—melanoma	2.89e-05	0.000294	CbGpPWpGaD
Valsartan—ALB—Metabolism—CSPG4—melanoma	2.89e-05	0.000294	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ITGB3—melanoma	2.87e-05	0.000292	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PRKCA—melanoma	2.87e-05	0.000292	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—SLC5A5—melanoma	2.87e-05	0.000292	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MTAP—melanoma	2.85e-05	0.00029	CbGpPWpGaD
Valsartan—ALB—Hemostasis—ITGB3—melanoma	2.84e-05	0.000288	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PRKCA—melanoma	2.84e-05	0.000288	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SPP1—melanoma	2.82e-05	0.000286	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAP2K2—melanoma	2.81e-05	0.000285	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCL8—melanoma	2.8e-05	0.000285	CbGpPWpGaD
Valsartan—ALB—Metabolism—GPAM—melanoma	2.8e-05	0.000284	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	2.79e-05	0.000283	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GNAQ—melanoma	2.77e-05	0.000282	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CD44—melanoma	2.77e-05	0.000282	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	2.71e-05	0.000276	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—melanoma	2.69e-05	0.000273	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL2—melanoma	2.68e-05	0.000272	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TERT—melanoma	2.67e-05	0.000271	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—ABCB1—melanoma	2.67e-05	0.000271	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RAC1—melanoma	2.66e-05	0.000271	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP1B1—melanoma	2.66e-05	0.00027	CbGpPWpGaD
Valsartan—ALB—Hemostasis—RAC1—melanoma	2.63e-05	0.000267	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—VEGFA—melanoma	2.58e-05	0.000262	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HIF1A—melanoma	2.55e-05	0.000259	CbGpPWpGaD
Valsartan—ALB—Hemostasis—MMP1—melanoma	2.54e-05	0.000259	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LUM—melanoma	2.54e-05	0.000259	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PHGDH—melanoma	2.54e-05	0.000259	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CDK2—melanoma	2.5e-05	0.000254	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HPSE—melanoma	2.49e-05	0.000254	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.46e-05	0.00025	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CUBN—melanoma	2.45e-05	0.000249	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KDR—melanoma	2.44e-05	0.000248	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—MAPK3—melanoma	2.44e-05	0.000248	CbGpPWpGaD
Valsartan—ALB—Metabolism—PLA2G6—melanoma	2.38e-05	0.000242	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SDHD—melanoma	2.36e-05	0.00024	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CSPG4—melanoma	2.36e-05	0.00024	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—BSG—melanoma	2.36e-05	0.00024	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FN1—melanoma	2.35e-05	0.000239	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CG—melanoma	2.35e-05	0.000239	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—melanoma	2.34e-05	0.000238	CbGpPWpGaD
Valsartan—ALB—Hemostasis—FN1—melanoma	2.32e-05	0.000236	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—MAPK1—melanoma	2.32e-05	0.000236	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOTCH1—melanoma	2.3e-05	0.000234	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS2—melanoma	2.29e-05	0.000233	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GPAM—melanoma	2.29e-05	0.000233	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PPARG—melanoma	2.26e-05	0.00023	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CD80—melanoma	2.25e-05	0.000229	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CG—melanoma	2.25e-05	0.000229	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KIT—melanoma	2.25e-05	0.000229	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APC—melanoma	2.25e-05	0.000229	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—NRAS—melanoma	2.25e-05	0.000229	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EGF—melanoma	2.22e-05	0.000226	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CG—melanoma	2.22e-05	0.000226	CbGpPWpGaD
Valsartan—ALB—Hemostasis—EGF—melanoma	2.2e-05	0.000223	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ABCB1—melanoma	2.19e-05	0.000222	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—MAPK3—melanoma	2.15e-05	0.000219	CbGpPWpGaD
Valsartan—ALB—Metabolism—VCAN—melanoma	2.14e-05	0.000217	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—BRAF—melanoma	2.11e-05	0.000215	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CD—melanoma	2.06e-05	0.00021	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IGF1—melanoma	2.06e-05	0.000209	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—MAPK1—melanoma	2.05e-05	0.000208	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—EGFR—melanoma	2.05e-05	0.000208	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALB—melanoma	2.04e-05	0.000207	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IGF1—melanoma	2.03e-05	0.000207	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	2.02e-05	0.000206	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CA—melanoma	2.01e-05	0.000205	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PRKCA—melanoma	2.01e-05	0.000205	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ERCC2—melanoma	2e-05	0.000203	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAP2K1—melanoma	1.99e-05	0.000202	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CD—melanoma	1.98e-05	0.000201	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CA—melanoma	1.96e-05	0.000199	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CD—melanoma	1.95e-05	0.000199	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARG—melanoma	1.95e-05	0.000198	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PLA2G6—melanoma	1.95e-05	0.000198	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—KRAS—melanoma	1.94e-05	0.000197	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FGF2—melanoma	1.89e-05	0.000192	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP17A1—melanoma	1.8e-05	0.000183	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CB—melanoma	1.8e-05	0.000183	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS2—melanoma	1.78e-05	0.000181	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	1.78e-05	0.000181	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CA—melanoma	1.78e-05	0.000181	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MDM2—melanoma	1.77e-05	0.00018	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—VCAN—melanoma	1.75e-05	0.000178	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ERBB2—melanoma	1.75e-05	0.000177	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CB—melanoma	1.72e-05	0.000175	CbGpPWpGaD
Valsartan—ALB—Metabolism—GNA11—melanoma	1.7e-05	0.000173	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CB—melanoma	1.7e-05	0.000173	CbGpPWpGaD
Valsartan—ALB—Metabolism—FASN—melanoma	1.67e-05	0.000169	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL8—melanoma	1.66e-05	0.000168	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	1.66e-05	0.000168	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.65e-05	0.000168	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—HRAS—melanoma	1.65e-05	0.000167	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—AKT1—melanoma	1.64e-05	0.000167	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC5A5—melanoma	1.64e-05	0.000167	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDKN1B—melanoma	1.62e-05	0.000164	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AKT1—melanoma	1.6e-05	0.000163	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—melanoma	1.6e-05	0.000162	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CASP3—melanoma	1.58e-05	0.000161	CbGpPWpGaD
Valsartan—ALB—Metabolism—GNAQ—melanoma	1.58e-05	0.000161	CbGpPWpGaD
Valsartan—ALB—Metabolism—CD44—melanoma	1.58e-05	0.000161	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL2—melanoma	1.58e-05	0.000161	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CG—melanoma	1.58e-05	0.00016	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6—melanoma	1.57e-05	0.00016	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IL2—melanoma	1.56e-05	0.000159	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTEN—melanoma	1.55e-05	0.000158	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.55e-05	0.000158	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCND1—melanoma	1.54e-05	0.000157	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.54e-05	0.000156	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CTNNB1—melanoma	1.53e-05	0.000155	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARG—melanoma	1.52e-05	0.000155	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP1B1—melanoma	1.52e-05	0.000154	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP9—melanoma	1.5e-05	0.000152	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDKN1A—melanoma	1.49e-05	0.000152	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTEN—melanoma	1.49e-05	0.000151	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NFKB1—melanoma	1.48e-05	0.000151	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP17A1—melanoma	1.48e-05	0.00015	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	1.46e-05	0.000148	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AKT1—melanoma	1.45e-05	0.000148	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—melanoma	1.44e-05	0.000146	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GNA11—melanoma	1.39e-05	0.000142	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CD—melanoma	1.39e-05	0.000141	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALB—melanoma	1.37e-05	0.000139	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—FASN—melanoma	1.36e-05	0.000139	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—VEGFA—melanoma	1.34e-05	0.000137	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC5A5—melanoma	1.34e-05	0.000136	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.34e-05	0.000136	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—STAT3—melanoma	1.33e-05	0.000135	CbGpPWpGaD
Valsartan—ALB—Hemostasis—VEGFA—melanoma	1.33e-05	0.000135	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NRAS—melanoma	1.33e-05	0.000135	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NRAS—melanoma	1.31e-05	0.000133	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CD44—melanoma	1.3e-05	0.000132	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GNAQ—melanoma	1.3e-05	0.000132	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAPK3—melanoma	1.27e-05	0.000129	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.27e-05	0.000129	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.26e-05	0.000128	CbGpPWpGaD
Valsartan—ALB—Hemostasis—MAPK3—melanoma	1.26e-05	0.000128	CbGpPWpGaD
Valsartan—ALB—Metabolism—ABCB1—melanoma	1.25e-05	0.000127	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP1B1—melanoma	1.24e-05	0.000126	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MYC—melanoma	1.24e-05	0.000126	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAPK1—melanoma	1.21e-05	0.000123	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EGFR—melanoma	1.21e-05	0.000123	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CB—melanoma	1.21e-05	0.000123	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS2—melanoma	1.2e-05	0.000122	CbGpPWpGaD
Valsartan—ALB—Hemostasis—MAPK1—melanoma	1.2e-05	0.000122	CbGpPWpGaD
Valsartan—ALB—Metabolism—PRKCA—melanoma	1.15e-05	0.000117	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KRAS—melanoma	1.14e-05	0.000116	CbGpPWpGaD
Valsartan—ALB—Metabolism—ERCC2—melanoma	1.14e-05	0.000116	CbGpPWpGaD
Valsartan—ALB—Hemostasis—KRAS—melanoma	1.13e-05	0.000115	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.1e-05	0.000111	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CA—melanoma	1.1e-05	0.000111	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CA—melanoma	1.05e-05	0.000107	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTEN—melanoma	1.04e-05	0.000106	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CA—melanoma	1.04e-05	0.000105	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCB1—melanoma	1.02e-05	0.000104	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TP53—melanoma	1.02e-05	0.000103	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TP53—melanoma	1e-05	0.000102	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HRAS—melanoma	9.72e-06	9.88e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—HRAS—melanoma	9.6e-06	9.76e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	9.45e-06	9.6e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PRKCA—melanoma	9.41e-06	9.57e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ERCC2—melanoma	9.34e-06	9.49e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6—melanoma	9.3e-06	9.45e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CG—melanoma	9.01e-06	9.16e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AKT1—melanoma	8.95e-06	9.1e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARG—melanoma	8.69e-06	8.84e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT1—melanoma	8.58e-06	8.72e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT1—melanoma	8.48e-06	8.62e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CD—melanoma	7.92e-06	8.05e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	7.73e-06	7.86e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CG—melanoma	7.37e-06	7.49e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CA—melanoma	7.36e-06	7.49e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARG—melanoma	7.12e-06	7.23e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CB—melanoma	6.9e-06	7.02e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS2—melanoma	6.84e-06	6.95e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CD—melanoma	6.48e-06	6.59e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALB—melanoma	6.4e-06	6.5e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AKT1—melanoma	6.02e-06	6.12e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTEN—melanoma	5.96e-06	6.06e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CB—melanoma	5.65e-06	5.74e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS2—melanoma	5.6e-06	5.69e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTEN—melanoma	4.88e-06	4.96e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CA—melanoma	4.21e-06	4.28e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CA—melanoma	3.44e-06	3.5e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKT1—melanoma	3.44e-06	3.49e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKT1—melanoma	2.81e-06	2.86e-05	CbGpPWpGaD
